Ixekizumab withdrawal may result in relapse in PsA
Among biologic‐naïve patients with psoriatic arthritis (PsA), continued ixekizumab therapy is more effective than discontinuation at sustaining low disease activity, according to data from a randomized, double‐blind withdrawal study.
